Phase 2 Study of Nivolumab and Entinostat in Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Request Access

Demographics (4)

COLLECTION_AGE - Age sample was collected (phv00542159.v1.p1)
GENDER - Self-reported gender (phv00542116.v1.p1)
ON_STUDY_AGE - Age of subject (phv00542115.v1.p1)
SEX - Biological sex (phv00542111.v1.p1)

Disease Events (37)

ADJUVANT_CHEMO_REGIMEN - Type of adjuvant chemotherapy received (phv00542123.v1.p1)
ADJUVANT_RT_Y_N - If adjuvant radiotherapy was received (phv00542124.v1.p1)
BEST_RESPONSE - Best response to treatment (phv00542152.v1.p1)
BL_CA19_9 - Baseline CA19-9 secretor status (phv00542135.v1.p1)
CA19_9_SECRETOR - CA19-9 secretor status (phv00542134.v1.p1)
DIFFERENTIATION - Differentiation status (phv00542120.v1.p1)
FGFR2_MUT_Y_N - FGFR2 mutation detected (phv00542140.v1.p1)
GENOMIC_ANALYSIS_Y_N - Genomic analysis done (phv00542137.v1.p1)
GROSS_LOCATION_OF_PRIMARY_TUMOR - Gross location of primary tumor within the pancreas (phv00542119.v1.p1)
IDH_MUT_Y_N - IDH mutation detected (phv00542139.v1.p1)
KRAS_MUT_Y_N - KRAS mutation detected (phv00542138.v1.p1)
LIVER_METS - Metastases presence in liver (phv00542148.v1.p1)
LN_METS - Metastases presence in lymph node (phv00542147.v1.p1)
LUNG_METS - Metastases presence in lung (phv00542149.v1.p1)
MAX_CA19_9_DECLINE - The maximum change of the CA19-9 while on therapy (phv00542136.v1.p1)
MSI_STATUS - MSI status (phv00542141.v1.p1)
NEOADJUVANT_CHEMO_REGIMEN - Type of neoadjuvant chemotherapy received (phv00542126.v1.p1)
NEOADJUVANT_CHEMO_Y_N - If neoadjuvant chemotherapy was received (phv00542125.v1.p1)
NEOADJUVANT_RT_Y_N - If neoadjuvant radiotherapy was received (phv00542127.v1.p1)
OS_EVENT - Overall survival event (phv00542144.v1.p1)
OS_TIME_MONTHS - Overall survival time (phv00542143.v1.p1)
OTHER_MUT - Other genomic mutations detected (phv00542142.v1.p1)
OTHER_SITES_OF_METASTASES - Metastases presence in other locations (phv00542151.v1.p1)
PERITONEAL_METS - Metastases presence in peritoneal (phv00542150.v1.p1)
PFS_EVENT - Progression-free survival event (phv00542146.v1.p1)
PFS_TIME_MONTHS - Progression-free survival time (phv00542145.v1.p1)
PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00542161.v1.p1)
RECIST - RECIST responder type (phv00542153.v1.p1)
STAGE_AT_DIAGNOSIS - Tumor stage at diagnosis (phv00542121.v1.p1)
SURGICAL_RESECTION - Surgery history (phv00542122.v1.p1)
THE_NUMBER_OF_PREVIOUS_LINES_OF_CHEMO - Number of previous lines of chemotherapy (phv00542132.v1.p1)
TUMOR_STAGE - Tumor stage of sample (phv00542162.v1.p1)
TUMOR_TREATMENT - Type of tumor treatment for sample (phv00542163.v1.p1)
X1ST_LINE_CHEMO_BEST_RESPONSE - Best response to chemotherapy (phv00542129.v1.p1)
X1ST_LINE_CHEMO_REGIMEN - First line of chemotherapy received (phv00542128.v1.p1)
X2ND_LINE_CHEMO_REGIMEN - Second line of chemotherapy received (phv00542131.v1.p1)
X2ND_LINE_CHEMO_Y_N - If the second line of chemotherapy was received (phv00542130.v1.p1)

Race and Ethnicity (2)

ETHNICITY - Self-reported ethnicity (phv00542118.v1.p1)
RACE - Self-reported race (phv00542117.v1.p1)

Other (12)

ANALYTE_TYPE - Analyte type (phv00542157.v1.p1)
BODY_SITE - Body site where sample was collected (phv00542156.v1.p1)
CONSENT - Consent group as determined by DAC (phv00542110.v1.p1)
IS_TUMOR - Tumor status (phv00542158.v1.p1)
PRIMARY_METASTATIC_TUMOR - Primary tumor, metastasis, or transformed cell line (phv00542160.v1.p1)
REASON_OFF_STUDY - Reason for leaving study (phv00542154.v1.p1)
SAMPLE_ID - Sample ID (phv00542155.v1.p1)
SAMPLE_ID - Sample ID (phv00542113.v1.p1)
SUBJECT_ID - Subject ID (phv00542114.v1.p1)
SUBJECT_ID - Subject ID (phv00542109.v1.p1)
SUBJECT_ID - Subject ID (phv00542112.v1.p1)
TIME_ON_STUDY__DAYS - Time on study (phv00542133.v1.p1)